Last $720.00 MXN
Change Today +27.60 / 3.99%
Volume 87.0
As of 4:09 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/30/14 - $720.00
52 Week Low
10/30/13 - $490.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVAN) Key Developments

Teva Pharmaceutical Industries Ltd. and Active Biotech to Present New Follow-Up Data Evaluating the Clinical Safety of Laquinimod in Patients with Relapsing-Remitting Multiple Sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. These data will be presented as part of a platform presentation, September 12, 2014, at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting being held in Boston, Massachusetts. In the pooled safety analysis, rates of adverse events (AEs) and serious AEs were lower in the open-label extensions than in the core studies and less than 3% of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod (1.18% reached >3xULN ALT vs. 4.72% for laquinimod and 2.6% for placebo during the core study). The safety analysis included patients exposed to laquinimod 0.6 mg for two or more years (n=1009), with a mean exposure of 3.7 (±1.0) years, in the double-blind phase and open-label extensions of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO trials.

Teva Pharmaceutical Industries Ltd. Announces New Data from the Open-Label Phase IIIb Glatiramer Acetate Low Frequency Safety and Patient ExpeRience (GLACIER) Study

Teva Pharmaceutical Industries Ltd. announced new data from the open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience (GLACIER) study, comparing the safety and tolerability of three-times-a-week COPAXONE (glatiramer acetate injection) 40 mg to daily COPAXONE 20 mg in patients with relapsing-remitting multiple sclerosis (RRMS). During a platform presentation this week, the results from the GLACIER study were shared at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting being held in Boston, Massachusetts. The primary endpoint of the GLACIER study, the adjusted mean annualized rate of injection-related adverse events (IRAEs), was achieved with a 50% reduction with the three-times-a-week COPAXONE 40 mg dosing regimen versus the daily COPAXONE 20 mg regimen. In a post-hoc analysis, a similar reduction in moderate/severe IRAEs was observed with the less frequent, three-times-a-week COPAXONE 40 mg arm relative to the daily COPAXONE 20 mg arm. The company said that these results provide supportive data that fewer injections with three-times-a-week COPAXONE 40 mg resulted in half as many reported IRAEs compared to the number of IRAEs with the COPAXONE 20 mg once-daily dosing regimen, said Michael Hayden, Teva's President of Global R&D and Chief Scientific Officer. In the GLACIER study, 209 patients who had received daily COPAXONE 20 mg for an average of 6.7 years, from 30 U.S. sites were randomized to receive COPAXONE 40 mg (n=108) or COPAXONE 20 mg (n=101). Patients were then assessed in the open-label design at months 1, 2 and 4. IRAEs included all local injection-site reactions (ISRs) and symptoms related to immediate post-injection reactions (IPIR; flushing, palpitations, anxiety, dyspnea) and were determined through patient diaries. Patient reported ISRs were classified as mild, moderate or severe. One patient in the 40 mg COPAXONE arm withdrew due to injection site necrosis. The overall safety was consistent with prior experience, and the study results will be submitted to a peer-reviewed publication. The less frequent IRAEs resulting from the reduction of dosing frequency from daily to three-times-a-week is an additional consideration for patients when making treatment decisions. This is useful data for physicians counseling their patients interested in transitioning from a daily to three-times-a-week injection schedule.

Teva Pharmaceutical Industries, Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Teva Pharmaceutical Industries, Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $720.00 MXN +27.60

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.59 USD -0.31
AbbVie Inc $57.76 USD -0.76
Baxter International Inc $71.77 USD -0.11
Covidien PLC $86.51 USD -1.30
Eli Lilly & Co $64.85 USD -0.49
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVAN Industry Range
Price/Earnings 17.6x
Price/Sales 2.2x
Price/Book 1.9x
Price/Cash Flow 19.7x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at